Lumos Pharma Inc reports results for the quarter ended in December - Earnings Summary

Lumos Pharma

08/03/2024 24:15

* Lumos Pharma Inc  LUMO.OQ  reported a quarterly adjusted
loss of
$1.17​​ per share for the quarter ended in December, lower than
the same quarter last year, when the company reported EPS of -99
cents.  The mean expectation of five analysts for the quarter
was for a loss of $1.15 per share. Wall Street expected
results to range from $-1.50 to -70 cents per share.
    * Revenue rose 61.3% to $826.00 thousand from a year ago;
analysts
expected $1.75 thousand. 
    * Lumos Pharma Inc's reported EPS for the quarter was a loss
of
$1.17​.
    * The company reported a quarterly loss of $9.46 million.
    * Lumos Pharma Inc shares had fallen by 5.3% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 3.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Lumos Pharma Inc
is $26.00 
This summary was machine generated from LSEG data March 8 at
12:14 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.15          -1.17          Missed
 Sep. 30 2023      -1.15          -1.04          Beat
 Jun. 30 2023      -1.10          -1.09          Beat
 Mar. 31 2023      -1.12          -0.89          Beat